Completed PHASE2 INTERVENTIONAL 1-arm NCT01276522

Efficacy and Safety of Canakinumab in Schnitzler Syndrome

Sponsor: Novartis

Interventions Canakinumab

Updated 6 times since 2017 Last updated: May 23, 2012 Started: Jan 31, 2011 Primary completion: May 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Schnitzler Syndrome, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands